Overview of Tussoret

Tussoret is a pharmaceutical preparation administered via the oral route as a solid tablet, with its identity defined by the active ingredient, Codeine.

Property	Description
Active ingredient	Codeine (often as the phosphate salt)
Form	Solid oral dosage form (tablet)
Pharmacological class	Antitussive and Opioid Analgesic
Common use	Relief of persistent, non-productive cough
Origin	Semisynthetic opioid alkaloid

Tussoret is classified as an Opioid Analgesic and, crucially for its therapeutic role, an Antitussive agent. Its classification as a CNS-acting drug differentiates it from topical or peripherally acting cough remedies. Codeine is clinically recognized for its efficacy as a centrally active cough suppressant, reducing the urge and frequency of coughing spasms.

Active Ingredient, Composition, and Origin

The single active substance in Tussoret is Codeine (INN), typically present as a salt such as Codeine phosphate. This alkaloid is a semisynthetic opioid, chemically derived from the naturally occurring opium alkaloid, morphine. As a pure active ingredient formulation, the composition centers exclusively on Codeine, which is manufactured into the tablet form using standard pharmaceutical excipients. The substance's semisynthetic origin ensures a controlled, consistent product quality.

General Therapeutic Purpose and Central Action

The general therapeutic purpose of Tussoret is the effective relief of persistent, non-productive coughs by modulating brain function. This symptomatic relief is achieved through a central action on the brain's cough center, which is responsible for triggering the involuntary spasms. The mechanism involves Codeine acting as a prodrug, which is metabolized to compounds that dampen the signals that initiate the cough reflex. This direct, suppressive effect is the fundamental benefit, intended to reduce the frequency and intensity of coughing spells.

What side effects are possible with Tussoret?

Possible Side Effects and Safety Information

The safety profile for Tussoret, which contains the opioid agonist Codeine, is primarily defined by the risks associated with opioid metabolism and activity on the central nervous and gastrointestinal systems. All reported adverse reactions and safety considerations are based on regulatory documentation from authorities such as the FDA and EMA.

Key Adverse Reactions and Classes

The most common adverse reactions reported are generally related to its CNS depressant effects, including drowsiness, lightheadedness, dizziness, and sedation. Gastrointestinal effects such as nausea, vomiting, and constipation are also frequently noted. Respiratory effects may include shortness of breath.

Classification	System-Organ Class Involved
Common	Nervous System, Gastrointestinal, Skin
Serious/Significant	Respiratory, Central Nervous System

Serious and Clinically Significant Safety Concerns

The most serious safety concerns are respiratory depression and toxicity, which can be fatal. This risk is critically linked to the body's metabolism of codeine into morphine by the CYP2D6 enzyme. Individuals who are Ultra-rapid Metabolizers are at a significantly heightened risk of toxicity, even at standard doses, due to the faster and more complete conversion to morphine.

Safety Restrictions and Limitations:

Pediatric Use: Codeine-containing products are contraindicated in children younger than 12 years of age for all indications and are not recommended in adolescents aged 12 to 18 years with certain underlying respiratory conditions (e.g., asthma, obstructive sleep apnea).
Post-Operative Use: The drug is generally contraindicated for post-operative management in children and adolescents younger than 18 years following tonsillectomy and/or adenoidectomy.
Genetic Risk: Contraindicated in patients of any age who are known to be CYP2D6 Ultra-rapid Metabolizers.
Other Contraindications: Use is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting, and in breastfeeding mothers.

Overall Safety Profile

The official safety structure emphasizes the high variability in patient response due to genetic polymorphism of the CYP2D6 enzyme, which dictates the risk of potentially fatal respiratory depression and toxicity. The primary risks extend to vulnerable populations, including children and those with compromised respiratory function. The regulatory focus is on minimizing these serious, metabolism-related risks through specific contraindications.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the Codeine overdose profile (Tussoret) by its profound depressant effects on the central nervous and respiratory systems.

Documented Manifestations

Overdose presentation involves symptoms of severe CNS depression, including extreme drowsiness, confusion, or a state progressing to coma. Physiological signs include slow or shallow breathing (respiratory depression) and long pauses between breaths, which may become life-threatening or fatal. Other documented clinical signs are pinpoint pupils, a slow heartbeat, and cold, clammy skin, potentially leading to shock.

Required Emergency Actions

Immediate medical attention must be sought if any manifestation of overdose is suspected. Regulatory guidance mandates calling emergency services immediately to prevent severe outcomes. The documented management strategy involves rapid administration of the opioid antagonist naloxone to reverse depressive effects, along with necessary breathing support (e.g., mechanical ventilation) and continuous monitoring of vital signs (e.g., ECG).

Population Risk Considerations

Specific risks are documented for certain groups. Accidental ingestion by children is cited as a serious risk factor that can result in a fatal overdose. Additionally, individuals identified as ultra-rapid metabolizers are noted as being susceptible to signs of overdose and life-threatening respiratory depression even when using the medicine at the prescribed dosage.

Therapeutic Uses of Tussoret

What Tussoret Treats: Main Uses and Benefits

Tussoret is primarily used to provide essential symptomatic relief across two distinct clinical domains. Its therapeutic applications are consistent with recognized medical practice for the active ingredient. The medication is generally applied across domains where additional symptomatic support is needed to address pronounced or challenging manifestations of discomfort.

Management of Non-Productive Cough Spasms

The medication is commonly used across conditions characterized by persistent, non-productive cough, which is a dry, hacking cough that creates noticeable physiological strain. This domain involves symptoms that interfere with daily functioning, often by causing frequent, disruptive spasms that affect rest. The primary indications relevant to its antitussive role include post-infectious cough and the management of chronic cough symptoms associated with certain respiratory conditions. The medication helps address these symptom clusters and contributes to easing the overall symptom load, offering symptomatic relief that may assist patients with maintaining a sense of stability.

Relief for Mild to Moderate Pain Symptoms

Tussoret is also relevant in contexts marked by increased discomfort or tension, as it helps in the management of mild to moderate somatic pain. This includes symptom groups related to physical discomfort arising from minor injuries or short-term pain following certain procedures. This application is often used during phases when symptoms become more noticeable and supportive relief is needed. It assists with maintaining functional stability and contributes to improved comfort during symptomatic periods by easing the overall pain burden.

Quick Fact: Relief for Persistent, Non-Productive Cough and Mild to Moderate Pain

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Tussoret — Official Regulatory Information

Eligibility Scope

Populations for whom use is allowed (as stated in label):

Adults (18 years and older).
Adolescents (12 to 18 years of age) who do not have respiratory compromise or require post-operative pain relief following tonsillectomy or adenoidectomy.

Populations for whom use is contraindicated:

All children younger than 12 years of age.
Adolescents younger than 18 years of age following tonsillectomy and/or adenoidectomy.
Breastfeeding mothers.
Patients of any age known to be CYP2D6 ultra-rapid metabolizers.
Patients with significant respiratory depression or acute/severe bronchial asthma.

Age-related eligibility rules:

Tussoret is strictly contraindicated for all children under 12 years. Use is not recommended for adolescents (12–18 years) who have conditions that compromise respiratory function, such as severe lung disease or obstructive sleep apnea. Older adults require closer monitoring due to increased sensitivity to respiratory effects.

Condition-specific eligibility rules:

Use requires caution in patients with severe hepatic impairment or severe renal impairment due to the drug's altered metabolism and elimination. The medicine is contraindicated during or within 14 days of taking Monoamine Oxidase Inhibitors (MAOIs). Contraindications also include known or suspected gastrointestinal obstruction, such as paralytic ileus.

Pregnancy and lactation eligibility status (if explicitly documented):

Pregnancy: Use with caution due to the potential for neonatal opioid withdrawal syndrome.
Lactation: Use is contraindicated.

Connection to the overall eligibility profile:

Official regulatory documents strictly define who can and cannot use Tussoret by establishing clear population boundaries through formal contraindications and mandated restrictions. These regulatory boundaries exclude populations based on age, metabolic risk, and specific clinical conditions like severe respiratory depression or GI obstruction. The official labeling limits eligibility to established populations and mandates special caution for those with compromised organ function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tussoret (Codeine) has officially documented interaction patterns primarily concerning metabolic enzyme pathways and additive central nervous system effects, as defined in regulatory documents.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated, and a minimum of 14 days must pass after discontinuing an MAOI before use. Additionally, the drug is contraindicated in individuals identified as CYP2D6 ultra-rapid metabolizers due to the high risk of life-threatening toxicity from excessive active metabolite exposure.

Pharmacodynamic and Metabolic Interactions

Combinations with other CNS Depressants, including alcohol, are associated with a severe risk of profound sedation, respiratory depression, coma, and death due to additive effects. Furthermore, co-administration with serotonergic drugs carries the documented potential for serotonin syndrome.

Metabolically, CYP2D6 inhibitors (e.g., quinidine) officially decrease the plasma concentration of the active metabolite, morphine, potentially reducing efficacy. Conversely, CYP3A4 inhibitors officially increase codeine plasma concentrations. Finally, combining Codeine with anticholinergic drugs increases the risk of severe constipation and urinary retention.

Mechanism of Action

Tussoret is an oral formulation containing codeine, a centrally acting opioid. Its pharmacodynamic activity is primarily mediated by its function as an agonist at mu-opioid receptors (mu-ORs) located in the central nervous system (CNS), particularly within the medulla oblongata's cough center.

Upon binding, mu-OR activation couples to inhibitory G-proteins (Gi/o). This G-protein coupling leads to a reduction in intracellular cyclic adenosine monophosphate (cAMP) synthesis via inhibition of adenylate cyclase. Downstream, this signaling cascade hyperpolarizes the neuronal membrane by promoting potassium ion efflux and inhibiting voltage-gated calcium channels.

At the system level, this molecular and cellular modulation decreases the excitability of afferent pathways in the cough center. The resulting dampening of neural signal transmission modifies the central processing of reflexogenic input. The overall physiological consequence is a reduction in the frequency and intensity of efferent signals emanating from the cough center.

Dosage and Administration Information

Official Administration Guidelines

Tussoret, which is an oral medication, is administered either as an immediate-release solid tablet or as an oral solution. The specific use pattern is governed by established limits regarding the dose, frequency, and overall duration of treatment.

Entity	Detail
Route of administration	Oral (tablet or solution)
Dosing schedule (Antitussive)	Typically 15 mg to 30 mg, repeated up to four times daily
Dosing schedule (Analgesia)	15 mg to 60 mg, repeated every 4 to 6 hours as needed
Maximum 24-Hour Dose	Up to 360 mg; lower limits (e.g., 240 mg) are applied in some regions

Administration Conditions and Constraints

The medicine can be taken with or without food, as this does not significantly alter its absorption. A minimum interval of not less than four hours must be observed between doses to ensure compliance with the daily maximum limit. For liquid formulations, the use of a calibrated measuring device is required to prevent dosing errors.

Age-group administration rules:

Official instructions strictly contraindicate the use of this medicine in children under 12 years of age. Furthermore, dose reductions may be necessary for older adults and patients with known hepatic or renal impairment.

Procedural Structure: Guidelines mandate that the lowest effective dosage be used for the shortest duration of time, with treatment for acute symptoms often limited to a maximum of three days.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tussoret

Evidence for use in Symptomatic Relief of Acute Cough

Research into the use of Tussoret for short-term relief of acute cough symptoms was studied for through randomized controlled trials (RCTs). These studies research examined various outcomes related to physical discomfort and outcomes describing episodic or acute changes, such as cough frequency and intensity, often measured over periods of one to two weeks. The populations included in these trials were generally adults experiencing acute cough.

The findings describe patterns observed in the studies where some trials reported measurements of patterns related to cough frequency during the study period compared to a placebo. Other studies described patterns such as changes in patient-reported outcomes describing perceived discomfort linked to coughing. However, the data show patterns related to symptom evolution that varied across different trials, and evidence remains limited and heterogeneous regarding the size and uniformity of these patterns across studies. The research provides insight into short-term changes observed in these specific study environments.

Evidence for use in Management of Chronic Bronchitis Symptoms

Research was evaluated in settings relevant to individuals with chronic bronchitis, which is a condition marked by functional limitations and conditions involving periods of heightened symptoms. Studies in this area, often involving longer observational cohorts or trials of moderate duration, applied in studies examining patient-reported experiences related to outcomes reflecting daily functioning or activity level, such as sputum production and overall respiratory discomfort.

Reported findings include observations of changes measured during the study period in a subset of the populations observed. Some studies reported measurements of patterns related to changes in the amount or thickness of sputum, while others described patterns observed related to symptom activity. However, the certainty remains low because the sample sizes were modest in many trials, and the definitions of "change" varied across studies.

Long-term Studies and Follow-up

For all indications, long-term effects are not fully established. Most of the available research studies focused on episodes where symptoms become more noticeable and provided information only for short time intervals. Research exploring short-term symptom changes cannot determine if any patterns measured are sustained over a durable period.

Evidence in Special Populations

Few data are available for groups outside of the general adult population. Research was studied for Tussoret has often excluded individuals with comorbid conditions or those at the extremes of age. The results apply only to the populations studied, meaning how relevant these findings are to special populations remains uncertain.

What is still uncertain about Tussoret

Existing studies provide limited insight into how individual characteristics may influence measured changes. The evidence is limited by modest sample sizes in many studies, and the follow-up durations were limited across the research landscape. Research does not determine whether an individual will respond similarly to the group patterns observed in the studies.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Tussoret (FAQ)

Q: How quickly can I expect Tussoret to start working for my cough?

A: Official information indicates that the onset of action for immediate-release codeine, the active component of Tussoret, is typically within 30 minutes to 1 hour after administration. It is important to understand that the full therapeutic effect may take longer. Information regarding administration guidelines should be reviewed with a healthcare professional.

Q: What is the usual duration of effect for one dose of Tussoret?

A: Regulatory information indicates that the effects of one dose of Tussoret typically last for approximately 4 to 6 hours. This duration aligns with the minimum time interval often required between doses. The minimum time interval between doses is part of the prescribing information that should be followed.

Q: Can Tussoret be taken with other cold and flu remedies?

A: Regulatory documents indicate a need for caution when combining Tussoret with other cold or flu remedies, particularly those that cause Central Nervous System (CNS) depression, such as certain antihistamines. The official labeling warns that mixing CNS depressants can lead to additive effects, increasing the risk of severe sedation and breathing difficulties.

Q: Can Tussoret be taken on an empty stomach?

A: According to the official administration guidelines, Tussoret can be taken with or without food. Taking the medication with food does not significantly change how the drug is absorbed by the body. This statement is noted in the official prescribing information.

Q: Is it normal to feel a mild euphoria or 'floaty' after taking Tussoret?

A: As an opioid medication, Tussoret affects the central nervous system. Common CNS effects noted in official documentation include dizziness, lightheadedness, and sedation. This effect, along with any other unusual sensations, should be discussed with a healthcare provider.

Q: Does Tussoret affect sleep patterns?

A: Yes, regulatory documents indicate that Tussoret can affect sleep. Side effects such as drowsiness, sedation, and trouble with sleeping (insomnia) have been reported. It is also noted that opioid use may be associated with sleep-related breathing problems.

Q: Does Tussoret affect a person's ability to drive or operate machinery?

A: Official warnings state that Tussoret may cause dizziness, drowsiness, confusion, or disorientation. Regulatory labeling includes a formal warning that individuals should refrain from driving or operating complex machinery until they understand the full effects of the medication on them.

Q: What should I do if I experience dry mouth while taking Tussoret?

A: Although dry mouth is a reported side effect of codeine, it is generally advised to discuss persistent or severe side effects with a healthcare provider to review options for symptom management. They can offer appropriate guidance.

Q: What if Tussoret doesn't seem to be working after a few days?

A: If the medicine seems less effective, regulatory documents caution against increasing the dose without consultation. Tolerance to the therapeutic effect of the opioid may occur with continued use. If the medicine does not provide adequate relief, it is appropriate to consult with a healthcare provider to review the current treatment plan.

Q: Is Tussoret the only brand name for this specific combination of ingredients?

A: Tussoret is a specific brand name for a product containing the active ingredient Codeine. According to regulatory and public health information, codeine is widely available under various other brand names and as a generic formulation.

Q: Does Tussoret work for all types of coughs?

A: Official product information is specific about the intended use of Tussoret. It is formally indicated for the relief of persistent, non-productive coughs (coughs that don't produce mucus or phlegm). The regulatory scope of the drug is specific and does not provide information for its use with all cough types.

Q: Does Tussoret have a risk of dependence or misuse?

A: Yes, Tussoret contains an opioid, and regulatory documents carry warnings that its use exposes individuals to the risks of addiction, abuse, and misuse. These risks can potentially lead to overdose. Physical dependence may also develop with continued use of the drug.

Q: Are there any non-cough related side effects I should be aware of with Tussoret?

A: Yes, the safety profile details effects beyond cough suppression. The most common adverse reactions reported are related to the nervous system (like drowsiness and dizziness) and the gastrointestinal system, including nausea, vomiting, and constipation.

Q: Is Tussoret a long-acting or short-acting formulation?

A: Based on the typical dosing schedule found in regulatory documents, which involves taking a dose every 4 to 6 hours, Tussoret is generally considered a short-acting medication. This is characteristic of immediate-release formulations.

Q: Is Tussoret available over the counter?

A: Tussoret contains the opioid codeine. In many government jurisdictions, medicines containing codeine are classified as controlled substances, meaning they are often only available with a prescription from a licensed healthcare provider due to the known risks of abuse and dependence.

Q: Can Tussoret cause a false positive on a drug test?

A: The active ingredient in Tussoret is an opiate. Official regulatory and toxicology information confirms that the legitimate use of codeine, even in therapeutic doses, can result in a positive test result for opiates.

Q: Is there a risk of respiratory depression with Tussoret?

A: Yes, official safety information states that Tussoret carries a risk of serious, life-threatening, or fatal respiratory depression (slowed or ineffective breathing). This risk is a primary safety concern, especially when initiating treatment or increasing the dose.

Q: Are there any dietary restrictions while taking Tussoret?

A: While major specific dietary restrictions are not widely listed, official guidance recommends that patients discuss all substances they consume, including herbal products or dietary supplements, with a doctor. It is generally recommended to discuss all supplements, including herbal products, with a doctor.

Q: Is Tussoret used for pain relief as well as cough?

A: Yes, Tussoret (Codeine) is officially classified by regulatory authorities as both an Antitussive (to suppress cough) and an Opioid Analgesic (to relieve pain). Its therapeutic scope includes both of these actions.

Q: Does Tussoret lose effectiveness if taken for too long?

A: Official warnings and precautions state that the development of tolerance to the effects of the opioid may occur after continued usage over a period of several days or weeks. This means the medicine may become less effective at the same dose.

Q: Is it true that Tussoret can affect the sphincter of Oddi?

A: Yes, the official prescribing information notes that codeine may cause spasm of the sphincter of Oddi. This is a muscle that regulates the flow of digestive fluids into the small intestine, and its spasm could potentially lead to an increase in pressure within the biliary system.

Q: Is it possible to become tolerant to the effects of Tussoret?

A: Regulatory documents confirm that tolerance to the therapeutic and adverse effects of the opioid may occur after continued use. This is a common physiological response to ongoing opioid exposure.

Q: Can Tussoret be used if I have a history of seizures?

A: Official patient guidance states that individuals with a history of seizures should inform their healthcare provider about their condition. Codeine is listed in some regulatory documents as potentially increasing the risk of seizures in patients with pre-existing seizure disorders.

How should Tussoret be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define strict storage and disposal requirements for Tussoret (Codeine) to maintain product stability and ensure public safety.

Storage Component	Requirement (Regulatory Basis)
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 25 C or allow freezing.
Protection	Keep the product in the original container, tightly closed, and protect from light and moisture.
Child Safety	Must be kept out of the sight and reach of children. Store in a secure, inaccessible location, such as a locked cabinet, due to the fatal risk of accidental ingestion.

Disposal: Unused or expired medication must be disposed of immediately.

The preferred method is using an authorized DEA drug take-back program or a mail-back envelope.
If take-back is unavailable, mix the tablets with an undesirable substance (like coffee grounds or dirt), place the mixture in a sealed container, and discard it in the household trash.

Tussoret